Title:Protein Interaction Networks in Metallo Proteins and Docking Approaches of Metallic Compounds with TIMP and MMP in Control of MAPK Pathway
VOLUME: 10 ISSUE: 1
Author(s):Kaladhar Svgk Dowluru, Potladurthi Chandra Sai, Padmanabhuni Venkata Nageswara Rao, Amajala Krishna chaitanya, Duddukuri Govinda Rao, Vadlapudi Varahala Rao, Potladurthi Suresh, Erva Rajeswara Reddy, Sudabattula Vijaya kumar, Divyakolu Vinod Kumar and Gajjala Bhaskar Reddy
Affiliation:GITAM Institute of Science, GITAM University, Rushikonda, Visakhapatnam-530045, India.
Keywords:MMP, TIMP, Metallic compounds, Protein-protein interactions, Docking, Anti-aging, Bioinformatics, Metalloproteins, ERK1/2, Pulmonary Disease
Abstract:Metalloprotein is a basic term for a proteins that contains a metal ion cofactor, have many functions in cells,
such as enzymes, transport and storage proteins, and signal transduction proteins. The balance between MMPs and TIMPs
are critical in extracellular matrix (ECM) development, morphogenesis, tissue repair and remodeling through MAPK
Pathway. Excess of MMPs and TIMPs shows adverse effects, leading to aging diseases such as Alzheimer’s Disease,
Cancer, Asthma, Diabetes 2 Mellitus etc. Human Protein Reference Dataset (HPRD) assessed 10 interactions for TIMP1,
5 interactions for TIMP2, 8 interactions for TIMP3 and 2 interactions for TIMP4. The data also assessed 11 interactions
for MMP1 and 11 interactions for MMP2. The data from HPRD and Pathwaylinker has also predicted the interaction of
Metalloproteins with aging diseases. In the present experimentation, in silico docking models predicted that Iron and
Cobalt are activators for TIMPs and MMPs. These metals can serve as an important reactants with good binding affinity
for TIMPs and MMPs. Except TIMP1 and TIMP2, all other TIMPs used in present experimentation have good binding
affinities with Cyanocobalamin. Hence Cyanocobalamine can be used in treatment of various diseases such as D2M,
Cancer, Alzheimer and Parkinson diseases in low dose for longer period, in control of MAPK pathway.
